References
- Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
- Nichols GA, Alexander CM, Girman CJ, et al. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care 2006;29:504-9
- Nichols GA, Alexander CM, Girman CJ, et al. Contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocr Pract 2007;13:37-44
- DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9
- Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
- Inzuchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72
- Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycemic therapies. Diabetes Obes Metabol 2007;9:96-102
- UKPDS Group. UKPDS 34: Effect of intensive blood-glucose control with metformin on complications on overweight patients with type 2 diabetes. Lancet 1998;352:854-65
- Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
- Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-40
- Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
- Lawrence DB, Ragucci KR, Long LB, et al. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12:466-71
- Battista RN. Implementing Preventive Services. New York, NY: American Journal of Preventive Medicine, 1988
- Karter AJ, Moffet HH, Liu J, et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007;13:598-606
- Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetes patients. J Int Med Res 2002;30:71-9
- DeFronzo RA. From the triumvariate to the ominus octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
- Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960-5
- Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50
- Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004;38:1357-62
- Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral antihyperglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411-15